The transaction, which is expected to close by the end of the month, will value the five-yearold company at $500-600 million, according to multiple sources aware of the development.
PharmEasy is closing in on $120m in equity round
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain